Iana I. Kokhanovskaia

Iana I. Kokhanovskaia

Auto-generated profile, based on publicly available information

Iana I. Kokhanovskaia

Sechenov First Moscow State Medical University (Sechenov University) Moscow, Russian Federation

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2023 in Diabetes mellitus
Verified
Journal Article
Open access
PDF file
YEYasmin El-Taravi
Yasmin El-Taravi
DBD. V. Baimukhambetova
D. V. Baimukhambetova
CGCyrill Gorlenko
Cyrill Gorlenko
HKHerman Kiselev
Herman Kiselev
IKI. Iu. Kokhanovskaia
I. Iu. Kokhanovskaia
ЯКЯ. Ю. Кохановская
Я. Ю. Кохановская
Fasting during the Islamic Ramadan month is one of the five obligatory pillars for each adult, healthy, and sane Muslim. People with severe illnesses, including type 1 and type 2 diabetes mellitus are exempt from fasting. However, many Muslims often insist on Ramadan participating despite any medical advises. It’s known that Muslims are the second largest religious group in Russia; thus, its crucial to have as much modern recommendation for management patients with type 1 and type 2 diabetes mellitus as possible. The aim of this narrative review is to evaluate physiological and pathophysiological metabolism changing during holy Ramadan month, to clarify the management of patients with type 1 and type 2 diabetes mellitus during Ramadan, to determine the frequency of glucose measuring during the day, and to understand when its time to interrupt the fasting. Moreover, we discuss specific recommendations in glucose-lowering therapy changing, nutrition, physical activities and education.

9 September 2025 in Research and Practical Medicine Journal
Verified
Journal Article
Open access
PDF file
IKI. Yu. Kokhanovskaia
I. Yu. Kokhanovskaia
AFAnastasia Fatyanova
Anastasia Fatyanova
ETEvgeny A. Tarabrin
Evgeny A. Tarabrin
IRI. V. Reshetov
I. V. Reshetov
ЯКЯ. Ю. Кохановская
Я. Ю. Кохановская
Подходы к лечению при легочных метастазах колоректального рака

21 February 2024 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
Marina I. SekachevaMarina I. Sekacheva
Marina I. Sekacheva
ARAlexander Rusanov
Alexander Rusanov
IKIana I. Kokhanovskaia
Iana I. Kokhanovskaia
КЮКохановская Яна Юрьевна
Кохановская Яна Юрьевна
Aim. Evaluation of comorbid pathology in SARS-CoV-2 infected in cancer practice as a predictor of severe outcomes. Testing the COVID-19 risk assessment tool in oncology (CORONET), to predict the likely severity of COVID-19 course in cancer patients on inpatient treatment. Materials and methods. A retrospective analysis of 173 cancer patient disease stories was conducted. The study was conducted as part of the program of the World-Class Research Center “Digital Biodesine and Personalized Health Care” of the University of Sechenov, with participation in the ESMO-CoCARE Register project. Based on the ESMO COVID-19 and CAncerREgistry (ESMO-CoCARE) registry, taking into account the entered our patient sample (n=173), a COVID-19 risk assessment tool in oncology (CORONET) was developed. Results. Cancer patients with comorbid pathology have been shown to have an increased risk of COVID-19 course of the disease from this sample by CORONET (mean conclusion score CORONET 2.44 pointsseverity). Prognosis of probable severity of outcomes in cancer patients infected with SARS-CoV-2 depends on associated diseases. The presence of a history of ≥3 comorbid pathologies in COVID-19 patients was detected in 106 people (61.27%). 15 patients were included in the risk of severe course. Retrospective analysis obtained actual confirmation of the prognosis of severe course of the disease in this group followed by death in all these patients (71.42% of all deaths). Indicators such as low albumin levels, high levels of C-reactive protein and neutrophils showed high prognostic significance of the likely severity of coronavirus infection in cancer patients on inpatient treatment for COVID-19. The mortality rate of patients admitted with COVID-19 and cancer was 12.14%. Conclusion. The most informative predictors of severe outcomes in COVID-19 in inpatient cancer patients to assess the prognosis of disease severity are: number of comorbidities, age, NEWS2 scale, ECOG patient activity status, albumin level, C-reactive protein level and absolute neutrophil level. The benefits gained in the use of the online decision support tool CORONET are considered convincing not only during the decision-making phase of hospitalization, but also in cancer patients on inpatient treatment.